Literature DB >> 20981120

Transplantation: can sirolimus prevent skin cancer in transplant recipients?

Edward K Geissler, Hans J Schlitt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20981120     DOI： 10.1038/nrneph.2010.130

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Sirolimus for Kaposi's sarcoma in renal-transplant recipients.

Authors:  Giovanni Stallone; Antonio Schena; Barbara Infante; Salvatore Di Paolo; Antonella Loverre; Giulio Maggio; Elena Ranieri; Loreto Gesualdo; Francesco Paolo Schena; Giuseppe Grandaliano
Journal:  N Engl J Med       Date:  2005-03-31       Impact factor: 91.245

2.  Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.

Authors:  Josep M Campistol; Josette Eris; Rainer Oberbauer; Peter Friend; Brian Hutchison; José M Morales; Kerstin Claesson; Giovanni Stallone; Graeme Russ; Lionel Rostaing; Henri Kreis; James T Burke; Yves Brault; Joseph A Scarola; John F Neylan
Journal:  J Am Soc Nephrol       Date:  2006-02       Impact factor: 10.121

3.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Authors:  Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

Review 4.  mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?

Authors:  Lionel Rostaing; Nassim Kamar
Journal:  J Nephrol       Date:  2010 Mar-Apr       Impact factor: 3.902

5.  Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy.

Authors:  Fu L Luan; Minoru Hojo; Mary Maluccio; Kouzaburo Yamaji; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2002-05-27       Impact factor: 4.939

6.  Cyclosporine induces cancer progression by a cell-autonomous mechanism.

Authors:  M Hojo; T Morimoto; M Maluccio; T Asano; K Morimoto; M Lagman; T Shimbo; M Suthanthiran
Journal:  Nature       Date:  1999-02-11       Impact factor: 49.962

7.  Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial.

Authors:  R Salgo; J Gossmann; H Schöfer; H G Kachel; J Kuck; H Geiger; R Kaufmann; E H Scheuermann
Journal:  Am J Transplant       Date:  2010-02-01       Impact factor: 8.086

Review 8.  Skin cancer in organ transplant recipients--where do we stand today?

Authors:  C Ulrich; J Kanitakis; E Stockfleth; S Euvrard
Journal:  Am J Transplant       Date:  2008-09-08       Impact factor: 8.086

Review 9.  mTOR, cancer and transplantation.

Authors:  Edward K Geissler; Hans J Schlitt; George Thomas
Journal:  Am J Transplant       Date:  2008-09-10       Impact factor: 8.086

Review 10.  Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.

Authors:  J W de Fijter
Journal:  Nephrol Dial Transplant       Date:  2007-05       Impact factor: 5.992
  10 in total
  2 in total

Review 1.  Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome.

Authors:  A M James Shapiro
Journal:  Rev Diabet Stud       Date:  2012-12-28

2.  Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease.

Authors:  Dana A Schaar; Filip Pirsl; Noa Holtzman; Seth M Steinberg; Jeannette Nashed; Claire Ruben; Edward W Cowen; Jacqueline W Mays; Sandra Mitchell; Alen Ostojic; Pashna N Munshi; Galen O Joe; Leora E Comis; Lindsay Morton; Steven Z Pavletic
Journal:  Transplant Cell Ther       Date:  2021-08-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.